Pure Global: Brazil's AI Device Maze - Decoding ANVISA's Unseen SaMD Hurdles

This week, we dive into a major regulatory shift in Latin America's largest market. Brazil's ANVISA has just rolled out a comprehensive and demanding new framework for Software as a Medical Device (SaMD), directly impacting AI-driven diagnostics and digital health platforms. We break down what these changes mean for market access. We explore the challenges through the case of a medical AI company. Their market entry plan for Brazil was solid, but the new regulations suddenly made their existing documentation obsolete. Now they face the critical risk of misclassifying their device, which could lead to costly delays and outright rejection by ANVISA. This episode is a must-listen for innovators looking to enter or expand in Brazil. Key Takeaways: - How does ANVISA's new risk classification for software differ from the FDA and EU MDR frameworks? - What are the most common documentation gaps that will lead to rejection under the new SaMD rules? - Are your current cybersecurity protocols sufficient to meet Brazil's stringent new requirements? - How can you leverage your existing clinical data for a successful Brazilian submission? - What specific post-market surveillance activities does ANVISA now expect from SaMD manufacturers? - Could this new regulation actually accelerate market entry for companies that are properly prepared? At Pure Global, we specialize in turning regulatory complexity into a competitive advantage. With our on-the-ground experts in Brazil and advanced AI-powered data tools, we provide end-to-end regulatory consulting to ensure your MedTech and IVD products achieve seamless market access. Don't let regulatory hurdles block your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can streamline your entry into over 30 global markets.